(Q40627397)

English

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319).

scientific article published on January 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Phase II clinical trial of didemnin B in patients with recurrent or refractory anaplastic astrocytoma or glioblastoma multiforme (NSC 325319). (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

phase II clinical trial

0 references

anaplastic astrocytoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Mittelman A

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Chun HG

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Puccio C

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Coombe N

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Lansen T

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Ahmed T

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

179-182

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

https://scigraph.springernature.com/pub.10.1023/a:1006379402114

0 references

Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of didemnin-B in advanced epithelial ovarian cancer. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of didemnin B in previously treated small cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Didemnin B in favourable histology non-Hodgkin's lymphoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antiproliferative agent didemnin B uncompetitively inhibits palmitoyl protein thioesterase

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of didemnin B (NSC #335319) in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II trial of trimetrexate or didemnin B for the treatment of metastatic or recurrent squamous carcinoma of the uterine cervix: a Southwest Oncology Group trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Didemnin B in metastatic malignant melanoma: a phase II trial of the Southwest Oncology Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of didemnin B in advanced adenocarcinoma of the kidney. A Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of didemnin B (NSC No. 325319) in advanced and recurrent cervical carcinoma: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of Didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of didemnin B in myeloma. A Cancer and Leukemia Group B (CALGB) study

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of didemnin B in advanced colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Brain tumor chemotherapy: an evaluation of agents in current use for phase II and III trials.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glioblastoma multiforme: pathology, natural history and treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increasing annual incidence of primary malignant brain tumors in the elderly.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Didemnin B. The first marine compound entering clinical trials as an antineoplastic agent

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical and pharmacological study of didemnin B in patients with metastatic breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I clinical trial of didemnin B

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II evaluation of didemnin B in hormonally refractory metastatic prostate cancer. A Southwest Oncology Group study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10638489

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1006379402114

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40627397&oldid=1534833780"